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AZD2461 is a poly (ADP) ribose polymerase (PARP) inhibitor developed as a follow-up to 
olaparib, the first PARP inhibitor approved for cancer therapy. Resistance to olaparib in 
BRCA knock-out models predominantly involves over-expression of P-glycoprotein. 
AZD2461 was selected as a poor substrate for drug transporters and we demonstrate efficacy 
in vivo against olaparib-resistant tumors that over-express P-glycoprotein. In addition, 
AZD2461 appeared better tolerated in combination with chemotherapy than olaparib, 
suggesting AZD2461 could have significant advantages in the clinic. However, the superior 
toxicity profile in mice does not extend to rats. As explanation, we show both differential 
PARP3 activity for olaparib and AZD2461 and a significantly higher PARP3 level in mouse 
bone marrow cells compared with rats and humans. These findings have implications for the 
use of mouse models to assess bone marrow toxicity for DNA-damaging agents and 
inhibitors of the DNA damage response. Structural modeling of the PARP3 active site with 
different PARP inhibitors also highlights the potential to develop compounds with different 
PARP family member specificity profiles designed for optimal anti-tumor activity and 
tolerability.
Length: 175 words (Limit 250)  
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Introduction 
Inhibitors of the DNA damage response (DDR) offer an exciting opportunity to identify 
targeted cancer therapies (1-3). In addition to enhancing the effectiveness of DNA-damaging 
chemotherapies and ionizing radiation (IR) treatment, DDR-inhibitors have the potential for 
single-agent activity in specific tumor genetic backgrounds based on the principle of 
synthetic lethality (4). This was first exemplified by inhibitors of the DDR protein poly(ADP-
ribose) polymerase (PARP) in Breast Cancer Associated (BRCA)-deficient genetic 
backgrounds that are associated with a high lifetime risk of breast and ovarian cancer (5, 6). 
The mechanism for this single-agent activity has been linked to the role of PARP in the repair 
of DNA single-strand breaks (SSBs) (7, 8) and DNA double-strand breaks (DSBs) (9, 10).
Following inhibitor treatment, PARP is trapped onto the unrepaired SSB, resulting in a 
protein-DNA adduct (11) that impedes replication fork progression, leading to replication 
fork collapse and the generation of the more genotoxic DSBs. These DSBs would normally 
be repaired by the homologous recombination repair (HRR) pathway (12), in which both 
BRCA1 and BRCA2 genes play pivotal roles (13). However, in tumors with HRR-defective 
backgrounds (e.g. because of BRCA deficiency), error-prone DNA repair pathways are 
utilized instead (9, 10, 14), resulting in the accumulation of genomic instability, chromosomal 
aberrations, and subsequently, cancer cell death. As a patients normal tissue ordinarily has a 
functional HRR pathway, this results in tumor-specific cell killing. 
Olaparib (AZD2281) is an oral and potent inhibitor of PARP activity (15) and the first PARP 
inhibitor to gain regulatory approval (16), (17). Olaparib demonstrates low nanomolar 
activity against PARP1 and PARP2 enzymes and only weak enzyme activity against 
tankyrase-1 (15). The vast majority of poly(ADP) ribosylation that can be detected in 
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mammalian cells is attributed to PARP1 (18), the key PARP protein involved in SSB repair, 
with PARP2 recognizing gaps and flap structures (19). 
Olaparib has demonstrated single-agent anti-tumor activity in patients with both BRCA-
mutant ovarian (20) and breast cancer (21), as well as in the broader serous ovarian cancer 
patient population, where patients who do not harbor BRCA mutations have also gained 
clinical benefit from single-agent olaparib treatment (22, 23). In this latter study, olaparib 
demonstrated a significant increase in progression-free survival (PFS) compared with placebo 
in patients with high-grade serous ovarian cancer in a maintenance setting. Olaparib was very 
well tolerated as a single agent and cessation of treatment was due primarily to tumor 
progression, most likely as a consequence of emerging tumor resistance.  
Currently, there is a paucity of data around resistance mechanisms associated with olaparib in 
the clinical setting. Preclinically, resistance mechanisms that have been identified in BRCA-
deficient tumors include the reactivation of BRCA2 gene reading frames by secondary 
mutations (24); the loss of 53BP1 (25, 26) or REV7 (27) in BRCA1;p53-deficient cancer 
cells, and the over-expression of the Abcb1a and Abcb1b genes encoding the mouse drug 
efflux transporter P-glycoprotein (P-gp), for which olaparib is a substrate. This last 
mechanism has been described in both BRCA1;p53-deficient (28) and BRCA2;p53-deficient 
(29) mouse mammary tumors. While the clinical significance of P-gp-based resistance for 
olaparib is still not clear, it may be of relevance in some cancers that are more commonly 
associated with high P-gp levels, e.g. colorectal cancers and acute leukemias. 
Here, we characterize a second-generation PARP inhibitor, AZD2461, derived from the same 
chemical series as olaparib, which retains the same level of anti-cancer cell potency (in vitro
and in vivo) but is differentiated from olaparib in terms of sensitivity to drug resistance 
mechanisms and PARP inhibitor profile.
7 
Materials and Methods 
Olaparib and AZD2461 PARP inhibitor compounds 
The PARP inhibitor olaparib (AZD2281, KU-59436) has been described previously (15). 
AZD2461 synthesis is described in the international patent WO2009/093032, specifically 
compound numbers 2b and 47. Formulation of compounds for in vivo studies is provided in 
Suppl Materials and Methods. 
Cell line and culture methods 
Human lung carcinoma A549 cells, breast cancer cell lines MDA-MB-436, T47D, BT549, 
MDA-MB231, SUM1315MO2, and SUM149PT, cervical cell lines HeLa, were grown in 
culture media conditions described in Suppl Materials and Methods. BRCA1 mutation 
status of breast cell lines has been described previously (30).  
Alkaline comet assay 
A549 cells were pre-treated for 1 hour at 37âC with 0.05% dimethyl sulfoxide (DMSO), 
olaparib, or AZD2461 (500 nM). Cells were treated with 30 Gy -IR (on ice) and allowed to 
recover at 37âC for the indicated time. SSBs (tail moments) were analyzed by alkaline comet 
assay as described (31). Comet tail moments were scored from 100 cells per experiment 
using Comet Assay IV (Perceptive Instruments). Two-way analysis of variance was carried 
out on the mean values for each time point from replicate experiments. 
Immunofluorescence 
For -H2AX analysis, A549 cells on cover slips were pre-incubated for 1 hour with DMSO or 
PARP inhibitors, and then irradiated (2Gy). The cells were incubated at 37ºC for the times 
8 
stated to allow repair. Cells were then immunostained for -H2AX foci, which were counted 
microscopically. For more details see Suppl Materials and Methods.  
PARP1, PARP2, and tankyrase isolated enzyme in vitro assays 
The activity (IC50) of PARP inhibitors was assessed against purified PARP1, PARP2, and 
tankyrase enzymes in vitro as described (15).  
PARP3 Bio-NAD in vitro assay  
PARP3 protein was prepared as described (32). A detailed protocol of the assay is described 
in Suppl Materials and Methods. In short, the ribosylation reaction mix was incubated with 
Bio-NAD+ (Trevigen) and Sau3A-cut peGFP-C1 plasmid (Clontech). Products were 
separated by SDS-PAGE, blotted onto nitrocellulose membrane, and signal detected using 
Streptavidin-HRRP (GE Healthcare). 
Clonogenic and cell proliferation assays 
Cells were detached from the flask using trypsin and washed with medium. The pellet was 
dislodged in growth medium into a single-cell suspension and counted in Nucleocounter. 
Cells were seeded in recommended dilutions (see Suppl Material and Methods) into 6-well 
plates in triplicates overnight. Olaparib and AZD2461 were prepared as 10 mM stock 
solution in 100% DMSO and added in final concentrations 0, 0.123, 0.37, 1.1, 3.3, and 10 
M to the cells. Plates were incubated at 37°C, 95% air, 5% CO2 until colonies of >50 have 
formed (approximately 714 days after dosing). Colonies were visualized by Giemsa staining 
(see Suppl Material and Methods) and scored using Colcount software (Oxford Optronix). 
Cellular IC50 values were determined for each cell line using Microsoft Excel and ID-BS 
XLfit (v4.2.2) charting application.  
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For sulphorhodamine B (SRB) assay, cells were seeded into 96-well plates (6000 cells/well) 
in 90 L of growth medium. In triplicate, AZD2461 or olaparib were added in final 
concentrations of 0, 1, 3, 10, 30, and 200 nM 1 hour prior to addition of 0, 3, 5, 7, 10, 12, and 
15 g/mL of MMS. Cells were incubated for 18 hours; then medium was replaced with 200 
L fresh medium. Plates were incubated for a further 72 hours before cells were fixed (10% 
trichloracetic acid, 100 L/well) for 30 minutes at 4ºC. Wells were washed with water and 
stained with 0.4% SRB (Sigma) in 1% acetic acid for 15 minutes at room temperature. 
Excess stain was removed by washing with 1% acetic acid and dry stained precipitate was 
dissolved with 100 L/well 10 mM Tris buffer. Absorbance was determined at 564 nM. Data 
are presented as percentage cell growth relative to untreated control. Cellular PF50
(potentiation factor at 50% cell survival) was calculated as the ratio of the IC50 for MMS 
alone versus MMS in combination with single concentrations of PARP inhibitors. 
Rodent experiments 
Brca1 5-13/5-13;p532-10/2-10 mammary tumors were generated in K14cre;Brca1 F5-13/F5-
13;p53F2-10/F2-10 mice and genotyped as described (33). Orthotopic transplantations of tumor 
fragments into syngeneic animals and caliper measurements of mammary tumors have been 
previously reported, along with the generation of the olaparib resistance tumor T6-28 (28). 
All treatments were started when tumor volume reached about 200 mm3 (v=length*width2/2). 
Olaparib (50 mg/kg intraperitoneally [i.p.]), tariquidar (2 mg/kg i.p.), or AZD2461 (100 
mg/kg orally [p.o.]) were given daily. Tariquidar was administered 30 minutes before 
olaparib. 
Mice (CD-1 Nude Foxn1nu, Charles River Labs, UK) were orally dosed once daily for 5 days 
with the combination therapies temozolomide (50 mg/kg) plus either olaparib (10 mg/kg) or 
AZD2461 (10 mg/kg) followed by once-daily dosing of olaparib or AZD2461 for an 
10 
additional 2 days. Rats (HsdHan:RNU-Foxn1rnu) were dosed orally once daily for 5 days with 
single agents or combination therapies (temozolomide 50 mg/kg, olaparib 10 and 20 mg/kg, 
or AZD2461 10 and 20 mg/kg). During the dosing phase, animals were weighed daily. For 
bone marrow analysis, mice were culled at day 4, 6 (n = 8 per group), and 8 (n = 3 per 
group). Rats (n = 8 per group) were culled on day 5 at 2 hours after the final dose. All 
experimental procedures were carried out according to current UK Home Office regulations. 
Flow cytometry analysis of bone marrow cells 
Bone marrow cells were prepared from rodent femurs as described in Suppl Materials and 
Methods and samples analyzed on a flow cytometer (FACS Canto, Becton and Dickinson, 
UK) using forward (FSC-H) and side scatter (SSC-H) on linear scales. 
RNA isolation and RT-PCR 
Total RNA was extracted from fresh bone marrow of six individual mice (CD-1 Nude 
Foxn1nu), six rats (HsdHan:RNU-Foxn1rnu), and human bone marrow mononuclear cells from 
six different individuals (Lonza 2M-125C) using RNeasy Mini kit (Qiagen) according to 
manufacturers instructions. To remove potential DNA contamination, the samples were 
DNase treated (RNase-Free DNase Set, Qiagen). RNA purity and concentration were 
determined spectrophotometrically (260/280 >1.9). RNA integrity was assessed on an 
Agilent 2100 Bioanalyzer using RNA 6000 Nano Chip. 
Human, rat, and mouse PARP1, 2, and 3 sequences were aligned using the Megalign module 
in DNAstar to facilitate design of primers and probes for both TaqMan and SYBR green 
qRT-PCR assays in areas of sequence identity. All sequences were also blast searched using 
the BLAST tool from the NCBI website to ensure target specificity. Assay efficiencies were 
calculated for each primer set to ensure template DNA from all species were amplified 
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similarly. Primers and probes were custom or catalogue ordered from Life Technologies 
(Invitrogen). Sequences are listed in Suppl Materials and Methods. 
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Results and Discussion 
Generation of the novel PARP inhibitor AZD2461 as a follow on to olaparib 
Based on emerging preclinical resistance data, we set about identifying a compound of 
similar efficacy to olaparib but without the potential liability associated with being a substrate 
for the P-gp (MDR1) transporter. Triaging of compounds following medicinal chemistry (see 
Suppl Materials and Methods) identified two series of compounds around the 
phthalazinone core of olaparib. AZD2461 (Fig. 1A) was identified as the optimal compound 
from the Piperidine Ether series (see international patent WO2009/093032, specifically 
compound number 2b and 47) and is a potent inhibitor of both PARP1 and PARP2 having 
enzyme IC50 values of 5 nM and 2 nM, respectively, comparable to that of olaparib (5 nM 
and 1 nM, respectively). The lack of selectivity between PARP1 and PARP2 may be 
considered a positive feature when attempting to inhibit SSB repair, as PARP2 also plays an 
important role in this pathway (34). To confirm that AZD2461 is as effective at inhibiting 
SSB repair as olaparib, we compared the ability of both compounds to inhibit the formation 
of cellular poly (ADP-ribose) (PAR) polymers following treatment with 10 mM hydrogen 
peroxide. AZD2461, like olaparib, was effective at inhibiting PAR formation in these assays 
(Suppl Fig. 1). To confirm that observed PAR inhibition translated into inhibition of SSB 
repair, we employed the alkaline COMET assay, where the length of the comet tail moment 
represents the degree of unrepaired SSBs following the induction of DNA damage by IR 
(Fig. 1B). We were also able to demonstrate that AZD2461 potentiated the anti-proliferation 
effect of the DNA-damaging alkylating agent methyl methanesulfonate (MMS), which 
induces SSBs (Fig. 1C and Suppl Table 1). 
Activity against BRCA-deficient tumors through synthetic lethality is a key component of 
olaparibs developmental program. Thus, we sought to determine the potency of single-agent 
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AZD2461 in BRCA-deficient cancer cells. In vitro clonogenic assays were performed with 
AZD2461 and olaparib against a panel of breast cancer tumor cells with either mutant (MDA-
MB-436, SUM1315MO2, and SUM149PT) or wild-type (WT) (T47D, BT549, and MDA-
MB-231) BRCA1 gene status. Both olaparib and AZD2461 exhibited similar PK and PD 
profiles (see Suppl Materials and Methods and Suppl Fig. 2) and significant potency as 
single agents in the BRCA1-mutant breast cancer cell lines but not in the BRCA1 WT cell 
lines (Fig. 1D)  
An assessment of in vitro permeability and efflux of AZD2461 was undertaken in the human 
intestinal-derived cell line CaCo-2 (see Suppl Materials and Methods and Suppl Table 2) 
and in the matched cell lines KBA1, a genetically modified version of HeLa that over-
expresses high levels of P-gp (35), and KB31, which does not over-express P-gp (Fig. 2A). 
While this functional assay does not distinguish between saturation of the P-gp pumps versus 
low binding, it does allow discrimination between compounds that are highly effluxed and 
those that are not. Using these two assays, we were able to distinguish low versus highly 
effluxed compounds, while addition of the P-gp inhibitor verapamil provided further 
evidence that efflux was occurring through a P-gp mechanism. The data in Fig. 2A show that, 
in contrast to olaparib, AZD2461 has similar activity between KBA1 cells and matched WT 
KB31 cells. Moreover, the addition of verapamil to KBA1 cells showed very little effect on 
the cellular activity of AZD2461, which indicated that AZD2461 is significantly less prone to 
the P-gp-mediated efflux mechanisms than olaparib. Similar data supporting a lack of P-gp 
liability were obtained in the colorectal cancer cell line HCT-15, which is characterized by 
high levels of endogenous Pg-P expression (Suppl Fig. 3 and Suppl Table 3).
To assess AZD2461 activity in the more clinically relevant BRCA-mutant background and 
acquired resistant setting, we used in vitro and in vivo models where prolonged treatment 
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with olaparib had led to resistance and high levels of P-gp expression. The BRCA2-deficient 
mouse breast cancer line KB2P3.4 was generated from a BRCA2-deficient mouse mammary 
tumor that demonstrated sensitivity to olaparib treatment (36). The KB2P3.4 cell line was 
treated in culture with olaparib for 2 months in order to induce the olaparib-resistant line 
KB2P3.4R, and over-expression of Pg-P was confirmed using immunofluorescence with a P-
gp antibody (Fig. 2B). Treatment of the parental KB2P3.4 with AZD2461 resulted in a 
similar response to olaparib (Fig. 2B). However, unlike olaparib, AZD2461 was also 
effective in the high P-gp-expressing KB2P3.4R cell line. Consistent with this difference 
being based on P-gp, the olaparib sensitivity in KB2P3.4R cells was restored on co-treatment 
with tariquidar, a new generation P-gp inhibitor. 
Increased expression of the Abcb1a and Abcb1b genes encoding the mouse drug efflux 
transporter P-gp contributes to olaparib resistance in BRCA1;p53-deficient mouse mammary 
tumors (28). To determine whether AZD2461 could overcome olaparib resistance in vivo, 
small tumor fragments of an olaparib-resistant tumor (T6-28) exhibiting an 80-fold increased 
expression of the Abcb1b gene were transplanted orthotopically into syngeneic WT female 
mice. When the tumor volume reached about 200 mm3, the animals were treated with 
olaparib, combination of olaparib with the P-gp inhibitor tariquidar, or with AZD2461. As 
expected, olaparib resistance was successfully overcome by tariquidar pre-treatment (Fig. 
2C). We also found that these tumors were sensitive to AZD2461 without the need for 
additional tariquidar treatment, consistent with the idea that spontaneous BRCA1;p53-
defective mammary tumors, in which resistance is caused by increased P-gp-mediated drug 
efflux, remain sensitive to AZD2461. Consistent with these findings, in a separate study, 
long-term AZD2461 treatment in the BRCA1;p53-defective mouse tumor model suppressed 
the development of drug resistance (37). 
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Together, these data demonstrate that AZD2461 is a potent inhibitor of PARP1 and PARP2 
that can provide effective inhibition of SSB repair and has significant single-agent activity in 
BRCA-deficient cancer cells, comparable to that of olaparib. Moreover, we have shown that 
AZD2461 is a poor substrate for P-gp and has activity in olaparib-resistant cancer cells that 
over-express P-gp in vitro and is capable of anti-tumor activity in vivo in olaparib-resistant 
tumors where resistance is based on the over-expression of P-gp. In this respect, the initial 
goal to develop a follow-on compound to olaparib that has comparable activity but without 
olaparibs P-gp liability has been successful. As a result, AZD2461 represents an excellent 
preclinical tool to study PARP inhibitor resistance, as it avoids this common mechanism of 
resistance and may help to identify additional mechanisms of PARP inhibitor resistance. 
AZD2461 is as efficacious as, and better tolerated than, olaparib in combination with 
temozolomide in a mouse xenograft model  
In addition to the utility of PARP inhibitors as single agents, there is also a strong rationale 
for combination with DNA-damaging chemotherapies such as temozolomide or 
camptothecins that induce SSBs (38, 39). As a single agent, the synthetic lethality of olaparib 
relies on the endogenously generated SSBs and the inability of BRCA mutation or other HRR 
deficiency to repair the ensuing DSBs, ultimately resulting in cancer cell death. In 
combination with DNA-damaging chemotherapies, the number of SSBs being generated by 
the chemotherapy agent is much larger than those that occur endogenously (40) and if repair 
is prevented (e.g. by treatment with a PARP inhibitor), cell death can be induced even when 
the HRR pathway is functional, purely because the DNA damage threshold that can be 
tolerated is exceeded. This has two important implications: first, a combination of a PARP 
inhibitor and SSB-inducing agent can result in the killing of HRR-proficient as well as HRR-
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deficient cancer cells; second, there is also the potential for increased damage in normal 
tissue compartments, which is evidenced in the increased hematological toxicities observed in 
patients when PARP inhibitors and alkylating agents are combined (41).  
To assess AZD2461 in combination with temozolomide in vivo, we used a mouse colorectal 
xenograft (SW620) model to compare the anti-tumor activity of 50 mg/kg temozolomide 
given once daily for 5 days either alone or in combination with 10 mg/kg AZD2461 or 
10 mg/kg of olaparib where the PARP inhibitors were given for 7 days. This dose and 
schedule of olaparib had previously demonstrated potentiation of temozolomide anti-tumor 
activity (Suppl Fig. 4A). The data presented in Fig. 3A show that, as expected, 
temozolomide alone demonstrated anti-tumor activity and that this was improved 
considerably by combining with a PARP inhibitor. Statistical analysis of the results on day 55 
(when the temozolomide treatment group was culled) showed that this difference was 
significant (p<0.001) and that the effect between the combination groups (i.e. temozolomide 
plus olaparib versus temozolomide plus AZD2461) was not statistically significant either at 
day 55 (p=0.53) or when the study was stopped at day 73 (p=0.57).  Moreover, both 
combination treatments conferred considerable delay in tumor re-growth compared with 
temozolomide alone. 
To examine the potential impact of AZD2461 in terms of tolerability, we looked at body 
weight loss as a gross indicator and at myelosuppression as a more clinically relevant 
indicator of combinatorial toxicity. Body weights of mice decreased relative to their weight at 
the start of the experiment but recovered quickly after the dosing was finished; weight loss 
was greater in the two combination groups (Suppl Fig. 5A). 
To assess the impact of the combinations on bone marrow populations compared with single 
agent chemotherapy, we took cohorts of mice and gave the same dose and regimen as used in 
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the combination efficacy study. Mice were culled at time points across the dosing phase to 
create a time course in which the impact of the treatments on the bone marrow cells could be 
assessed (Fig. 3B and 3C). At the designated time points, femurs were excised and bone 
marrow cells flushed out and counted using flow cytometry. Using forward and side scatter 
parameters, three distinct white blood cell populations could be identified (lymphocytes, 
monocytes, and neutrophils) and these data showed that alone, temozolomide led to a 
reduction in the total number of white blood cells in bone marrow with the nadir after the last 
dose and a failure to return to the starting levels at day 8. Temozolomide in combination with 
olaparib led to a significantly greater impact on bone marrow (a nadir at day 6 and a worse 
state of recovery at day 8).  
An unexpected finding, however, was that AZD2461 in combination with temozolomide did 
not result in the same severity of bone marrow effects as the olaparib combination. In fact, 
the nadir was not statistically different from temozolomide alone and there was a good 
recovery by day 8. Although lower doses of olaparib could result in less bone marrow 
toxicity, these are also likely to be less efficacious, as demonstrated by Suppl Fig. 4, which 
shows that doses of 3 mg/kg of olaparib and below in combination with temozolomide (50 
mg/kg) do not confer a statistically significant benefit over temozolomide alone (maximum 
tolerated dose 68 mg/kg). 
Taken together, these data suggest that AZD2461 might have two potential advantages over 
olaparib. First, while having a similar level of anti-tumor activity, AZD2461 did not have the 
same level of P-gp liability as olaparib; second, AZD2461 appeared better tolerated in 
combination with a DNA-damaging chemotherapy. The basis for this latter observation, 
though, could not obviously be attributed to PARP1/PARP2 inhibition, as AZD2461 and 
olaparib are similar in this respect, suggesting an as yet unidentified mechanism.  
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AZD2461 and olaparib have differential activity against PARP3 
One possible explanation for the hematological toxicity differences observed between 
olaparib and AZD2461 could be differential PARP3 activity. The PARP3 protein plays an 
important role in non-homologous end joining (NHEJ), where it is stimulated by DSBs in 
vitro and it functions in the same pathway as the PAR-binding protein APLF to accelerate 
chromosomal DSB repair (32). Following IR treatment, phosphorylated histone H2AX 
(H2AX) can be used as a marker of DSB damage (42, 43). The repair of DSBs and the 
decline in H2AX over time following IR was abrogated by either the loss of PARP3, APLF, 
or treatment with the PARP inhibitor KU-58948, which is related chemically to olaparib (32).  
The link between PARP3, NHEJ, and mouse bone marrow was highlighted in studies of 
murine hematopoietic stem and multipotent progenitor cells (HSPCs), which were shown to 
be more resistant to IR-induced damage than more differentiated progenitor cells (44). This 
difference was based on both an increased resistance to apoptosis and the ability to repair 
DNA by NHEJ. The NHEJ pathway is a less reliable alternative to HRR DSB repair, and 
mice bone marrow stem cells appear to utilize NHEJ while human HSPCs undergo apoptosis 
in response to a DNA damage insult instead (45). It has been suggested that the different 
ways the hematopoietic cells from mice and humans handle DNA damage may reflect the 
different challenges faced by mammals with diverse life spans and ages of reproductive 
maturity (46). 
To investigate whether differential PARP3 activity could provide the basis for the differential 
hematological toxicity observed with olaparib and AZD2461 in mice, we looked at the effect 
of both of these PARP inhibitors on H2AX following IR treatment (Fig. 4A). Unlike 
olaparib, which results in persistence of H2AX following IR to the same degree as APLF 
knockdown, AZD2461 had no effect on H2AX dynamics. To confirm if this observation 
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was due to PARP3 inhibition, we carried out PARP3 enzyme inhibition assays where PARP3 
auto-ADP-ribosylation activity was assessed following the addition of increasing doses (2.5 
nM1.5 M) of olaparib or AZD2461. Fig. 4B shows that AZD2461 did not inhibit PARP3 
to the same extent as olaparib. There was a 50-fold difference in PARP3 activity, with the 
IC50 value for PARP3 being 4 nM for olaparib and 200 nM for AZD2461 (Fig. 4B). The data 
in Fig. 4A, C, and D suggest this difference at the enzyme level is sufficient to translate into 
a failure to inhibit NHEJ DSB repair, based on H2AX kinetics. 
Increased bone marrow tolerability of AZD2461 in combination with temozolomide is 
mouse specific and is not seen in rat models 
The finding that AZD2461 does not inhibit PARP3, coupled with previous studies that 
suggest mouse bone marrow HSPCs preferentially use NHEJ when dealing with DNA 
damage, suggests the observation of better tolerability of chemotherapy combination reported 
here could be specific to mice and not translate into humans. Prior to initiating clinical trials 
to test whether AZD2461 was better tolerated with chemotherapy than olaparib, we looked to 
repeat the experiment presented in Fig. 3 but in an athymic rat model. First we assessed 
PARP3 levels (and compared with PARP1 and PARP2 levels) in HSPCs from mice, rats, and 
humans (Fig. 5 and Suppl Fig. 6 and Suppl Fig. 7). We found that PARP3 levels were 
about 3.7 times higher in mice than in rats (Fig. 5A), consistent with their use of NHEJ as a 
primary repair mechanism. Because of a lack of the same sequence identity, it was not 
possible to directly compare levels of PARP3 expression across mice, rats, and human bone 
marrow cells using the TaqMan probe-based assay. However, using SYBR green dye 
detection RT-PCR, we designed specific primers for human and rat PARP3 and demonstrated 
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that the relative level of PARP3 expression is very similar between rat and human bone 
marrow cells (Fig. 5B).
In order to increase confidence around the finding of better hematological tolerability, we 
repeated the temozolomide combination study depicted in Fig. 3C in an athymic rat model 
(Fig. 5C). Contrary to the result we obtained in mice, we observed that AZD2461 was no 
better tolerated than olaparib in terms of bone marrow toxicity (Fig. 5C) or total body weight 
loss (Suppl Fig. 5B and Suppl Fig. 5C). A repeat of this experiment in male athymic rats 
(data not shown) confirmed these results. This observed difference could not obviously be 
explained by differences in PK between mice and rats, as they are comparable (10 mg/kg in 
both cases giving an area under the curve [AUCt] of 12 mol.h/L). 
Here, we have provided an explanation for the better tolerability observed in mice by 
providing data showing the differential PARP3 activity for olaparib and AZD2461, and the 
different impact of the two compounds on NHEJ DSB repair as inferred by the effects on the 
recovery of radiation-induced H2AX. To date, technical challenges around the isolation and 
analysis of rat HSPCs have prevented us from directly demonstrating that rats are different 
from mice in utilizing NHEJ and therefore we cannot formally rule out alternative reasons for 
combination toxicity differences observed between the two rodent species. However, the 
clinical experience of combining PARP inhibitors with temozolomide (41) does argue that rat 
and not mouse is the better predictive model. 
Structural analysis of the PARP3 active site 
Previous studies have made the observation that PARP3 differs from PARP1 and PARP2 in 
the D-loop structure within the catalytic domain (47). A sequence alignment of this region 
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(Fig. 6, Suppl Materials and Methods) shows that PARP3 contains a shorter loop within 
this region versus PARP1 and PARP2. A graphical model of the PARP3 crystal structure 
bound to PARP inhibitor KU58948 is shown in Fig. 6,see also (47), with the variant region 
highlighted. The model shows that PARP3 may be more restrictive for binding by PARP 
inhibitors with charged or extended groups beyond the carbonyl linker region of these 
molecules, whereas the PARP1 and PARP2 structures have a more extended D-loop and may 
be more permissive for inhibitor binding. Fig. 6 also shows a comparison of the chemical 
structures of KU58948, olaparib and AZD2461, with the variable groups beyond the linker 
region highlighted. This illustrates that derivatives of olaparib could be generated for 
selectivity for or against PARP3 by targeting the variable region in the PARP3 D-loop 
structure. 
The demonstration of differential PARP3 activity of AZD2461 compared with olaparib has 
two important ramifications. First, we are only just beginning to understand the biological 
roles of the different PARP family members and their interplay. For example, this study 
demonstrates that AZD2461 could represent a useful tool to distinguish the cellular functions 
of PARPs 13 in DNA repair. Specifically, previous in vitro studies have shown that PARP3 
preparations can activate PARP1, and it has been suggested that PARP3 plays a role in 
regulating the DNA damage response through PARP1 activation (48).  However, our study 
shows that in cells treated with AZD2461, PARP3 is active in the NHEJ pathway even in the 
absence of detectable PARP1 activity, suggesting that the roles of PARP1 and PARP3 in 
chromosomal DNA repair are, in fact, independent. Second, the structural similarity between 
olaparib and AZD2461 that results in this observed differential activity against PARP3 has 
allowed a rationalization of the mechanistic basis of this difference in specificity via the 
modeling of the PARP inhibitors in the PARP3 active site.
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An increase in our understanding of inhibitor-PARP family member interactions, as 
demonstrated by an independent study (49), will also facilitate our understanding of PARP 
family biology. Together, advances in both an ability to generate inhibitors with a particular 
PARP specificity profile, as has been demonstrated very recently (50), along with an 
understanding of the biological roles of the different PARP family members, should provide 
the opportunity to generate inhibitors with the optimal PARP inhibitory profile to maximize 
anti-tumor activity and therapeutic index. 
Acknowledgments 
This work was supported by AstraZeneca. Tariquidar was a kind gift of Dr. Susan Bates from 
the NHI. The authors would also like to thank Stephen Moore, James Harrison, Gabrielle 
Grundy, Antony Oliver, Cydney Morgan and Eva Schut for their technical support.  
Editorial support was provided by Kerry Acheson, PhD, of iMed Comms, Macclesfield, UK, 
and funded by AstraZeneca. 
23 
References  
1. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev 
Cancer 2012;12:801-17. 
2. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 
2012;481:287-94. 
3. O'Connor MJ, Martin NM, Smith GC. Targeted cancer therapies based on the inhibition of 
DNA strand break repair. Oncogene 2007;26:7816-24. 
4. Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat 
Rev Cancer 2005;5:689-98. 
5. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing 
of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 
2005;434:913-7. 
6. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the 
DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21. 
7. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the 
regulation of nuclear functions. Biochem J 1999;342 ( Pt 2):249-68. 
8. Lindahl T, Satoh MS, Poirier GG, Klungland A. Post-translational modification of 
poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci 
1995;20:405-11. 
24 
9. Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI, et al. 
Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair. 
Nature 2015;518:258-62. 
10. Mateos-Gomez PA, Gong F, Nair N, Miller KM, Lazzerini-Denchi E, Sfeir A. 
Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination. 
Nature 2015;518:254-7. 
11. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of 
PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 2012;72:5588-99. 
12. Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability 
and suppresses tumorigenesis. Nat Rev Mol Cell Biol 2010;11:196-207. 
13. Venkitaraman AR. Cancer suppression by the chromosome custodians, BRCA1 and 
BRCA2. Science 2014;343:1470-5. 
14. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-
ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. 
Proc Natl Acad Sci U S A 2011;108:3406-11. 
15. Menear KA, Adcock C, Alonso FC, Blackburn K, Copsey L, Drzewiecki J, et al. Novel 
alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase. Bioorg Med Chem Lett 
2008;18:3942-5. 
16. European Medicines Agency (EMA). Lynparza recommended for approval in ovarian 
cancer, 2014. Available at 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10/news_
detail_002196.jsp&mid=WC0b01ac058004d5c1, accessed on 19 October 2015. 
25 
17. US Food and Drug Administration (FDA). FDA News Release: FDA approves Lynparza 
to treat advanced ovarian cancer, 2014. Available at 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm, accessed 
on 23 June 2015. 
18. Mullins DWJ, Giri CP, Smulson M. Poly(adenosine diphosphate-ribose) polymerase: the 
distribution of a chromosome-associated enzyme within the chromatin substructure. 
Biochemistry 1977;16. 
19. Fisher AE, Hochegger H, Takeda S, Caldecott KW. Poly(ADP-ribose) polymerase 1 
accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase. Mol 
Cell Biol 2007;27:5597-605. 
20. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et 
al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 
mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51. 
21. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral 
poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 
mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44. 
22. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. 
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian 
carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-
randomised study. The Lancet Oncology 2011;12:852-61. 
23. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib 
maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 
2012;366:1382-92. 
26 
24. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to 
therapy caused by intragenic deletion in BRCA2. Nature 2008;451:1111-5. 
25. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, et al. 
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-
mutated breast cancers. Nat Struct Mol Biol 2010;17:688-95. 
26. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, et al. 53BP1 inhibits 
homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. 
Cell 2010;141:243-54. 
27. Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, et al. REV7 
counteracts DNA double-strand break resection and affects PARP inhibition. Nature 
2015;521:541-4. 
28. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. 
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 
alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008;105:17079-
84. 
29. Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, et al. Poly(ADP-ribose) 
polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary 
tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 
2009;69:3850-5. 
30. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, et 
al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new 
deleterious mutants. Cancer Res 2006;66:41-5. 
27 
31. Breslin C, Clements PM, El-Khamisy SF, Petermann E, Iles N, Caldecott KW. 
Measurement of chromosomal DNA single-strand breaks and replication fork progression 
rates. Methods Enzymol 2006;409:410-25. 
32. Rulten SL, Fisher AE, Robert I, Zuma MC, Rouleau M, Ju L, et al. PARP-3 and APLF 
function together to accelerate nonhomologous end-joining. Mol Cell 2011;41:33-45. 
33. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, et al. 
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human 
BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A 2007;104:12111-6. 
34. Ame JC, Rolli V, Schreiber V, Niedergang C, Apiou F, Decker P, et al. PARP-2, A novel 
mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 
1999;274:17860-8. 
35. Choi KH, Chen CJ, Kriegler M, Roninson IB. An altered pattern of cross-resistance in 
multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-
glycoprotein) gene. Cell 1988;53:519-29. 
36. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, et al. Selective 
inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin 
Cancer Res 2008;14:3916-25. 
37. Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, et al. Loss of 
53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer 
Discov 2013;3:68-81. 
38. Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J 
Cancer 2011;105:1114-22. 
28 
39. Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, et al. Rationale for poly(ADP-
ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or 
temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 
2014;349:408-16. 
40. Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, et al. 
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and 
activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) 
polymerase-1. Clin Cancer Res 2005;11:3402-9. 
41. Plummer R, Lorigan P, Evans J, Steven N, Middleton M, Wilson R, et al. First and final 
report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, 
in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma. J 
Clin Oncol 2006;24(Suppl):Abstract 8013. 
42. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. 
GammaH2AX and cancer. Nat Rev Cancer 2008;8:957-67. 
43. Riballo E, Kuhne M, Rief N, Doherty A, Smith GC, Recio MJ, et al. A pathway of 
double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to 
gamma-H2AX foci. Mol Cell 2004;16:715-24. 
44. Mohrin M, Bourke E, Alexander D, Warr MR, Barry-Holson K, Le Beau MM, et al. 
Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell 
Stem Cell 2010;7:174-85. 
45. Milyavsky M, Gan OI, Trottier M, Komosa M, Tabach O, Notta F, et al. A distinctive 
DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent 
role for p53 in self-renewal. Cell Stem Cell 2010;7:186-97. 
29 
46. Lane AA, Scadden DT. Stem cells and DNA damage: persist or perish? Cell 
2010;142:360-2. 
47. Lehtiö L, Jemth AS, Collins R, Loseva O, Johansson A, Markova N, et al. Structural basis 
for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem 
2009;52:3108-11. 
48. Loseva O, Jemth AS, Bryant HE, Schuler H, Lehtio L, Karlberg T, et al. PARP-3 is a 
mono-ADP-ribosylase that activates PARP-1 in the absence of DNA. J Biol Chem 
2010;285:8054-60. 
49. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG, et al. 
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat 
Biotechnol 2012;30:283-8. 
50. Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, et al. Discovery of 2-[1-
(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoind ole-4-
carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 
Inhibitor for Cancer Therapy. J Med Chem 2015;58:6875-98. 
30 
Figure legends 
Fig. 1. AZD2461 has comparable effects on DNA single-strand break repair and efficacy 
as olaparib in vitro. A, Chemical structure of the PARP inhibitors AZD2461 and olaparib 
and respective enzymatic IC50 against PARP1 and PARP2. B, Human A459 cells were pre-
incubated in the presence of 500 nM olaparib or AZD2461 and then subjected to ionizing 
radiation treatment. SSB repair was quantified using the alkaline comet assay. Graph and 
statistical analyses were derived from three independent experiments. C, AZD2461 
potentiates the activity of the alkylating agent MMS in the HeLa cell line when used in 
combination and assessed using an SRB 96-well assay. D, Clonogenic survival assays were 
used to assess the single-agent activity of AZD2461 and olaparib and then IC50 values 
determined. Both olaparib and AZD2461 demonstrate potent single-agent activity against 
BRCA1-deficient breast cancer cell lines MDA-MB-436, SUM1315MO2, and SUM149PT, 
but are significantly less active against the breast cancer lines T47D, BT549, and MDA-MB-
231 that have wild-type BRCA1. IC50 values of greater than 10 M have been recorded as 
equal 10 M. Data were generated from three independent experiments. 
Fig. 2. AZD2461 overcomes P-gp-associated resistance to olaparib. A, Activity of 
AZD2461 and olaparib in the matched cell lines KBA1 (a genetically modified version of 
HeLa that over-expresses high levels of P-gp) and KB31 that does not over-express P-gp. B, 
Immunofluorescence staining for P-gp protein expression in the parental KB2P3.4 BRCA2-/-
mouse cell line and an acquired olaparib-resistant clone KB2P3.4R and relative growth 
inhibition in parental KB2P3.4 BRCA2-/- mouse cell line and an acquired olaparib-resistant 
clone. C, Response of the olaparib-resistant Brca15-13/5-13;p532-10/2-10 tumor T6-28 to 
AZD2461. Animals carrying orthotopically transplanted tumors were treated daily with 10 
mL 0.5% HPMC (vehicle) per kg p.o., 100 mg AZD2461 per kg p.o., 50 mg olaparib per kg 
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i.p., or 2 mg tariquidar per kg i.p. and 50 mg olaparib per kg i.p. when tumors reached a 
volume of 150 to 250 mm3 (100%, day 0). 
Fig. 3. AZD2461 is as effective as olaparib in potentiating the anti-tumor efficacy of 
temozolomide and shows lower impact on mouse bone marrow cells. A, Anti-tumor 
activity of AZD2461 and olaparib in combination with temozolomide in an SW620 tumor 
xenograft model. Mice were dosed orally once daily for 5 consecutive days with the 
combination therapies followed by once-daily dosing of the PARP inhibitor for an additional 
2 days. Tumor volumes were plotted relative to the first day of dosing. Comparisons were 
made to the single agent temozolomide (one-sided) and between the AZD2461 combination 
and olaparib combination groups (two-sided) employing Students t-test comparisons using 
pooled inter-animal variability. B, Kinetics of nucleated cells in mouse bone marrow 
following treatment with AZD2461 and olaparib in combination with temozolomide. Mice 
bone marrow samples were analyzed 24 hours after the third, fifth, and seventh dose by flow 
cytometry using forward (FSC-H) and side scatter (SSC-H) on linear scales. C, Mouse bone 
marrow analysis on day 5 of treatment demonstrates the impact of temozolomide with and 
without the two different PARP inhibitors on the total population of nucleated cells.   
Fig. 4. AZD2461 inhibits PARP3 to a lesser extent than olaparib, which results in a lack 
of inhibition of non-homologous end-joining repair in cancer cells. A, AZD2461, unlike 
olaparib, does not impact on DSB repair kinetics in human A549 cells. Following pre-
incubation with 500 nM olaparib or AZD2461, cells were irradiated with 2 Gy IR and 
allowed to recover for the times indicated. DSBs were detected by H2AX 
immunofluorescence. A stable APLF knockdown cell line is shown as a control for cells 
lacking PARP3/APLF-dependent NHEJ (APLF KD). Graph shows the mean +/- SEM from 
four independent experiments. B, AZD2461 is a much weaker inhibitor of PARP3 than 
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olaparib. PARP activity assay used 200 nM PARP3 in the presence of olaparib or AZD2461 
at the concentrations shown. Assays were carried out in the presence of 25 M Biotin-NAD 
and 200 ng Sau3Al-cut plasmid DNA. Products were separated by SDS-PAGE and detected 
using streptavidin-HRRP and ECL. PAR signal integrated density was quantified by ImageJ 
software and was used to assess AZD2461 and olaparib IC50 values for PARP3 inhibition. C, 
Repair of DSBs in primary PARP3 +/+ or D, PARP3 -/- mouse embryonic fibroblasts. Cells 
were pre-treated with 500 nM olaparib or AZD2461 before being subjected to 2 Gy IR and 
allowed to repair for the indicated times. The average number of H2ax foci per cell is 
shown. Graph shows the mean +/- standard error of the mean from four independent 
experiments. ** = p<0.01, *** = p<0.0001 by paired t-test. 
Fig. 5. PARP3 levels are significantly higher in mouse but not rat or human bone 
marrow cells and consistent with this is a lack of differential bone marrow toxicity 
between AZD2461 and olaparib in rats. A, PARP1, PARP2, and PARP3 gene expression 
were analyzed in mouse and rat bone marrow cells using customized TaqMan assays cross-
reacting and performing with comparable efficiencies in both species. Comparative 
quantification of genes expression was based on six biological samples. Rat average Ct was 
used as the reference level to calculate fold change differentials for each sample. A two-tailed 
t-test with Welchs correlation was applied to analyze differences between gene expression in 
rat versus mouse (PARP1 means difference = 0.1517, p = 0.0632; PARP2 means difference 
-0.3883, p = 0.0318; PARP3 means difference = -3.717, p = 0.0169) B, PARP3 gene 
expression in rat and human bone marrow cells was measured by SybrGreen RT-PCR assay. 
Rat average Ct was used as the reference level to calculate fold change differentials for each 
sample (biological n = 6). A two-tailed t-test with Welchs correlation was applied to analyze 
differences between gene expression in rat versus human tissue (PARP3 means difference -
0.01548, p=0.9232). Box-and-whiskers graphs show mean from three experimental repeats. 
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C, Female athymic rat bone marrow analysis (day 5 of treatment) using flow cytometry 
analysis as in Fig. 3C. The graph represents the mean ± SD of total nucleated cell population 
(% of parent) in individual treatment groups (n = 3). 
Fig. 6. Comparison between the catalytic domains of PARP1 and PARP3. Sequence 
alignment of a portion of the catalytic domains of PARPs 1, 2, and 3 highlights residues 
forming the “HYE triad” within the catalytic core (green arrows) and a PARP3-specific 
deletion (grey box) are shown. The model shows the PARP3 crystal structure bound by the 
PARP inhibitor KU58948 (magenta) with the putative PARP3 selectivity pocket shown in 
yellow and “HYE triad” residues in green. The right panel shows a closer image of the PARP 
inhibitor pocket with the PARP3 variant region in yellow and the corresponding PARP1 
structure aligned in cyan. Also shown are the chemical structures of the PARP inhibitors 
KU58948, olaparib, and AZD2461, with the variable side chains thought to be contributing to 
PARP3 selectivity highlighted. 
